about
Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinomaRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerCancer-related inflammationInflammation and cancer: back to Virchow?Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancerSmoldering and polarized inflammation in the initiation and promotion of malignant diseaseBortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancersp21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophagesActivity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.Tumor necrosis factor or tumor promoting factor?Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.The role of cytokines in the epithelial cancer microenvironment.Chemokine biology in cancer.B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.Antiproliferative and antitumor activity of TNF in vitro and in vivo.Interleukin-6 as a therapeutic target in human ovarian cancerAdaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.A dynamic inflammatory cytokine network in the human ovarian cancer microenvironmentThe inflammatory cytokine network of epithelial cancer: therapeutic implications.Centre of the Cell: Science Comes to Life.Paraneoplastic thrombocytosis in ovarian cancer.Interleukin-6 Stimulates Defective Angiogenesis.Activity of type IV collagenases in benign and malignant breast diseaseRecombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trialCXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.Rethinking ovarian cancer: recommendations for improving outcomes.Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.Immunology for the next generation.Induction and suppression of glutathione transferases by interferon in the mouse.Human interferons inhibit experimental metastases of a human melanoma cell line in nude miceTNF-alpha in promotion and progression of cancer.Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts.
P50
Q22011025-1610BE62-C073-43A8-A687-FC50EBB6AF48Q26780387-7E5788CF-CF3F-4A35-8B44-6AD6CD9E25C9Q27860907-4F794026-DD99-4B91-BB75-CBA368DEE407Q28036756-DE40B5B6-058C-42B5-9626-D8283178B069Q28168748-9FF4FAF1-21C2-42FD-A8DB-BB6DB73935E2Q29618034-DA221F23-D2A5-4222-A9CC-347602C1B6D7Q33370812-C6815D49-2BEA-4CB0-8AE8-4375F6E2D0DCQ33719793-ADDAC82D-6CC1-431D-A88F-B6F6A8DCCBDEQ33997928-B4FDF11D-E4E2-4365-8617-DBE7D78CA996Q34119854-0FA657FF-6AF5-44D0-AB5F-A86540A313E3Q34187879-7658A385-F091-4818-8F68-35E4BF3851A8Q34326476-6D1CB5C0-0035-4B0D-9ACA-ACC1536A561AQ34447344-6CE4B0C1-5F92-4F9B-95C3-0A1718C926CFQ34568701-2E281E23-7F0F-4892-BB4A-84279A94D423Q34621683-ECBDD138-D3C9-46D4-B77F-EEB6EC16E978Q34655020-C14F8336-9FD2-4463-85C7-4FD273BAA7EEQ35031912-6D1734FD-6FBC-40C6-BFC5-C0DA921F8B19Q35081453-4CE01383-D47F-412F-AFC3-A45FAD92D8C2Q35215812-68A832EE-C969-4E58-9997-87097FF7D89EQ35226167-3977247D-1C52-4835-AA6B-5BEC32517DAEQ35239088-2CAB7AAF-E9CB-4D22-81AD-4329746965F6Q35264283-21D17D28-F57A-435D-B454-65FC6052C0F6Q35578568-A47AF63E-6741-44A2-9758-560206993DD2Q35656974-AEE11D96-0448-4428-A6EB-41A8C33DB569Q35694258-4FCFC958-4FDE-4956-BB30-107838B94D1AQ35764672-C7950B9A-AD76-4991-BAC2-9BD59B972023Q35812402-26265DA5-C09B-4056-B8D1-EB9C0507B465Q35923153-1FDBA673-F22E-4186-B7E7-24460541177CQ35976755-E904AF7F-2E68-4053-8AEA-DF2315447F2EQ35991589-C1A603D7-B3C1-49B9-8881-1392A4474834Q36041701-E12EDFF4-50EE-4864-A817-6D684D5B4F6EQ36043441-6170BA8B-5A63-41E7-BC0F-BEA1657490D9Q36050883-7454AC28-B59A-429A-90E8-4B0517D440ABQ36081325-21432688-1CCF-456D-8BB3-3D08055E304BQ36133150-52CD2D0F-8AD2-40FC-B698-E0632C33DCB7Q36464737-BB653264-B766-4910-9D11-BFD9AB505483Q36466341-F0C489EE-5143-4D22-B018-1AE40F156EF0Q36585132-E2492E5F-E1C6-4FC5-95E9-FB10BCB0BB5FQ36617341-109B7D91-9BE9-41A8-821D-52A140995FE1Q36617945-3F2CC8A7-D06B-4EFD-A337-41597F57EFF8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Frances R Balkwill
@ast
Frances R Balkwill
@en
Frances R Balkwill
@es
Frances R Balkwill
@sl
type
label
Frances R Balkwill
@ast
Frances R Balkwill
@en
Frances R Balkwill
@es
Frances R Balkwill
@sl
prefLabel
Frances R Balkwill
@ast
Frances R Balkwill
@en
Frances R Balkwill
@es
Frances R Balkwill
@sl
P1006
P214
P244
P1006
P106
P21
P213
0000 0001 2380 2047
P214
P244
P31
P496
0000-0002-5587-9759
P569
1950-01-01T00:00:00Z
P734
P735
P7859
lccn-n87907833